TrialThe Journal of infectious diseases2024

Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.

Emilie R Elliot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.